Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1377185 | Bioorganic & Medicinal Chemistry Letters | 2007 | 5 Pages |
Abstract
Nitrofuranyl isoxazolines with increased proteolytic stability over nitrofuranyl amides were designed and synthesized leading to discovery of several compounds with potent in vitro anti-tuberculosis activity. However, their in vivo activity was limited by high protein binding and poor distribution. Consequently, a series of non-nitrofuran containing isoxazolines were prepared to determine if the core had residual anti-tuberculosis activity. This led to the discovery of novel isoxazoline 12 as anti-tuberculosis agent with a MIC90 value of 1.56 μg/mL.
Graphical abstractDiscovery of isoxazoline compound 12 as novel anti-tuberculosis agent (MIC90 = 1.56 μg/mL) is reported.Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Rajendra P. Tangallapally, Dianqing Sun, Rakesh, Nageshwar Budha, Robin E.B. Lee, Anne J.M. Lenaerts, Bernd Meibohm, Richard E. Lee,